Vanguard Portfolio Management LLC filed an amended beneficial ownership statement with the SEC on October 30, 2026, disclosing a 1.33% stake in Rocket Pharmaceuticals Inc (NASDAQ:RCKT) as of September 30, 2026.

Key Highlights

  • Total beneficial ownership: Vanguard Portfolio Management reported aggregate beneficial ownership of 1,463,677 shares of Rocket Pharmaceuticals common stock.
  • Percent of class: The reported position represents 1.33% of the outstanding common stock, according to the filing.
  • Sole dispositive power: Vanguard Portfolio Management holds sole power to dispose of all 1,463,677 shares, with no shared dispositive power reported.
  • Sole voting power: Sole voting power is reported for only 37,351 shares, with 0 shares subject to shared voting power.
  • Triggering date: The event requiring this filing occurred on September 30, 2026, per the disclosure.
  • Affiliated entities included: The filing states that reported holdings include securities attributable to Vanguard Fiduciary Trust Company and Vanguard Global Advisers, LLC.

Vanguard Portfolio Management Discloses Amended Position in Rocket Pharmaceuticals

According to the filing, Vanguard Portfolio Management LLC, organized in Pennsylvania and headquartered at 100 Vanguard Blvd., Malvern, PA 19355, submitted this amended statement as an investment adviser classified under SEC reporting rules. The disclosure covers common stock of Rocket Pharmaceuticals Inc, a clinical-stage gene therapy company headquartered at 430 East 29th Street, Suite 1040, New York, NY 10016, whose shares trade on NASDAQ:RCKT under CUSIP number 77313F106.

The filing states that the reported holdings reflect securities "beneficially owned, or deemed to be beneficially owned" by Vanguard Portfolio Management LLC and two affiliated entities: Vanguard Fiduciary Trust Company and Vanguard Global Advisers, LLC. The disclosure specifies that holdings include securities held by Vanguard funds, or sleeves thereof, over which Vanguard Portfolio Management LLC exercises dispositive power, as well as securities held by clients over which the named affiliates exercise dispositive and/or voting power. The filing further notes that holdings of other Vanguard subsidiaries or affiliates whose ownership is disaggregated under SEC Release No. 34-39538 are not included.

The filing certifies, per Item 10, that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." No single other person's interest in the reported securities exceeds 5%, according to the disclosure. The statement was signed by My Trieu-Gatt, identified as Authorized Signatory and Head of Global Fund Administration for Vanguard Portfolio Management.

What Was Disclosed

Vanguard Portfolio Management reported an amended beneficial ownership position of 1,463,677 shares, or 1.33%, of Rocket Pharmaceuticals common stock as of September 30, 2026, with sole dispositive power over all reported shares and sole voting power over 37,351 shares.